Skip to main content

Advertisement

SpringerLink
Log in

Arzneimittelnebenwirkungen bei antiretroviraler Therapie

The side effects of antiretroviral therapy

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Einführung der hochaktiven antiretroviralen Therapie (HAART) führte nicht nur zu einer eindrücklichen Senkung der Morbidität und Mortalität der HIV-infizierten Patienten, sondern auch zu gastrointestinalen, hepatischen oder metabolischen Nebenwirkungen. An frühen Arzneimittelreaktionen werden allergische Exantheme, Hypersensitivitätsreaktionen, Immunrekonstitutionsphänomene und Injection-Site-Reaktionen gesehen. Im Verlauf der Therapie können Fettstoffwechselstörungen, Blutzuckerentgleisungen oder Transaminaseerhöhungen auftreten. Bei den Spätreaktionen imponiert das Lipodystrophiesyndrom, die Kombination einer peripheren Fettabnahme und einer zentralen Fettzunahme.

Abstract

The introduction of highly active antiretroviral therapy (HAART) has resulted in tremendous improvements in morbidity and mortality in HIV-infected patients. However, the use of these drugs has coincided with an increasing number of reports of gastrointestinal, hepatic or metabolic side effects. Soon after beginning antiretroviral treatment drug rashes, hypersensitivity reactions, immune reconstitution syndrome or injection site reaction are frequently seen. Under HAART dyslipidemia, impaired glucose metabolism and elevated liver function are observed. In the later treatment phase, lipodystrophy, a combination of peripheral lipoatrophy and central fat accumulation, occurs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Ball RA, Kinchelow T (2003) Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49: 826–831

    Article  PubMed  Google Scholar 

  2. Barreiro P, Soriano V, Casas et al. (2000) Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 14: 2153–2157

    Article  PubMed  Google Scholar 

  3. Behrens G, Dejam A, Schmidt H et al. (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63–F70

    Article  PubMed  Google Scholar 

  4. Birkus G, Hitchcock MJ, Cihlar T (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 716–723

    Article  PubMed  Google Scholar 

  5. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356: 1423–1430

    Article  PubMed  Google Scholar 

  6. Carr A, Emery S, Law M et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361: 726–735

    Article  PubMed  Google Scholar 

  7. Dalakas MC (2001) Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6: 14–20

    Article  PubMed  Google Scholar 

  8. Dube MP, Stein JH, Aberg JA et al. (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37: 613–627

    Article  PubMed  Google Scholar 

  9. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN et al. (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15: 1843–1848

    Article  PubMed  Google Scholar 

  10. Friis-Moller N, Weber R, Reiss P et al. (2003) Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179–1193

    Article  PubMed  Google Scholar 

  11. Gulick RM, Mellors JW, Havlir D et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734–739

    Article  PubMed  Google Scholar 

  12. Hartmann M, Petzoldt D (2000) [Lipodystrophy syndrome in HIV infection]. Hautarzt 51: 159–163

    PubMed  Google Scholar 

  13. Hartmann M, Brust J, Schuster D et al. (2005) [Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz]. Hautarzt 56: 847–853

    Article  PubMed  Google Scholar 

  14. Hewitt RG (2002) Abacavir hypersensitivity reaction. Clin Infect Dis 34: 1137–1142

    Article  PubMed  Google Scholar 

  15. Hoigne R, Hunziker T (1999) [Maculopapular exanthema: should suspected drugs continue to be used?]. Schweiz Med Wochenschr 129: 823–824

    PubMed  Google Scholar 

  16. Izzedine H, Isnard-Bagnis C, Hulot JS et al. (2004) Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 18: 1074–1076

    Article  PubMed  Google Scholar 

  17. Kontorinis N, Dieterich DT (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23: 173–182

    Article  PubMed  Google Scholar 

  18. Liechty CA, Solberg P, Mwima G et al. (2005) Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 19: 993–994

    Article  PubMed  Google Scholar 

  19. Mallal S, Nolan D, Witt C et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359: 727–732

    Article  PubMed  Google Scholar 

  20. Martin AM, Nolan D, James I et al. (2005) Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19: 97–99

    PubMed  Google Scholar 

  21. McLeod GX, Hammer SM (1992) Zidovudine: five years later. Ann Intern Med 117: 487–501

    PubMed  Google Scholar 

  22. Moore RD, Keruly JC, Chaisson RE (2001) Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 15: 617–620

    Article  PubMed  Google Scholar 

  23. Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22: 911–936

    Article  PubMed  Google Scholar 

  24. Peyriere H, Reynes J, Rouanet I et al. (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269–273

    PubMed  Google Scholar 

  25. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM (2003) Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 83: 1–9

    Article  PubMed  Google Scholar 

  26. Schambelan M, Benson CA, Carr A et al. (2002) Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 31: 257–275

    PubMed  Google Scholar 

  27. Sherman DS, Fish DN (2000) Management of protease inhibitor-associated diarrhea. Clin Infect Dis 30: 908–914

    Article  PubMed  Google Scholar 

  28. Smith DE, Jeganathan S, Ray J (2006) Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials 7: 34–38

    Article  PubMed  Google Scholar 

  29. Temesgen Z, Beri G (2004) HIV and drug allergy. Immunol Allergy Clin North Am 24: 521–31

    Article  PubMed  Google Scholar 

  30. Van LF, Phanuphak P, Ruxrungtham K et al. (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 363: 1253–1263

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Universitätshautklinik, Voßstraße 2, 69115 , Heidelberg, Deutschland

    M. Hartmann

Authors
  1. M. Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Hartmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartmann, M. Arzneimittelnebenwirkungen bei antiretroviraler Therapie. Hautarzt 57, 969–974 (2006). https://doi.org/10.1007/s00105-006-1240-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-006-1240-6

Schlüsselwörter

Keywords

Search

Navigation